News articles about Innoviva (NASDAQ:INVA) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.8628650715248 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
A number of equities analysts have recently issued reports on INVA shares. Zacks Investment Research downgraded Innoviva from a “hold” rating to a “sell” rating in a report on Tuesday, February 20th. TheStreet raised Innoviva from a “c+” rating to a “b” rating in a report on Friday, February 9th. ValuEngine raised Innoviva from a “hold” rating to a “buy” rating in a report on Wednesday, March 7th. Stifel Nicolaus reaffirmed a “hold” rating and set a $17.00 price target on shares of Innoviva in a research note on Friday, February 9th. Finally, BidaskClub raised Innoviva from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Two research analysts have rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Innoviva currently has an average rating of “Hold” and an average target price of $13.83.
INVA stock traded down $0.33 during trading on Friday, hitting $16.46. The stock had a trading volume of 434,114 shares, compared to its average volume of 753,987. Innoviva has a 1-year low of $11.02 and a 1-year high of $17.21. The company has a market capitalization of $1,709.63, a price-to-earnings ratio of 14.07 and a beta of 2.17. The company has a current ratio of 5.77, a quick ratio of 5.77 and a debt-to-equity ratio of -2.37.
Innoviva (NASDAQ:INVA) last announced its earnings results on Thursday, February 8th. The biotechnology company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.01. The firm had revenue of $69.52 million during the quarter, compared to the consensus estimate of $67.41 million. Innoviva had a net margin of 61.76% and a negative return on equity of 48.93%. The firm’s revenue for the quarter was up 59.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.22 EPS. research analysts predict that Innoviva will post 1.99 earnings per share for the current year.
In other news, VP George B. Abercrombie sold 8,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $16.51, for a total transaction of $132,080.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Desparbes sold 5,378 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $16.52, for a total value of $88,844.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/innoviva-inva-receiving-somewhat-positive-news-coverage-study-shows.html.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.